NCT06621251 - Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Prosthetic Joint Infections of HipProsthetic Joint Infections of Knee

Interventions

DRUG

TRL1068 (calpurbatug), a human monoclonal antibody

A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

PROCEDURE

DAIR

DAIR procedure will be performed between days 15-22

Trial Locations (17)

10003

RECRUITING

NYU Langone Health, New York

14623

RECRUITING

University of Rochester, Rochester

21215

RECRUITING

Sinai Hospital Baltimore, Baltimore

28412

RECRUITING

M3 Wake Research Associates, Wilmington

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

33321

RECRUITING

Phoenix Clinical Research, Tamarac

34232

NOT_YET_RECRUITING

Gulfcoast Research Institute, Sarasota

72205

RECRUITING

University of Arkansas for Medical Sciences (UAMS), Little Rock

75087

RECRUITING

North Texas Medical Research Institute, Rockwall

77030

RECRUITING

Houston Methodist, Houston

RECRUITING

Paradigm Research Center, Houston

77555

RECRUITING

University of Texas Medical Branch at Galveston, Galveston

78520

NOT_YET_RECRUITING

Proactive RGV, Brownsville

84112

RECRUITING

University of Utah, Salt Lake City

85234

RECRUITING

OrthoArizona, Gilbert

90024

RECRUITING

UCLA, Los Angeles

02120

RECRUITING

New England Baptist Hospital, Boston

All Listed Sponsors

lead

Trellis Bioscience LLC

INDUSTRY